Stockscreener 앱 받기
4.23
0.24%
-0.010
시간 외 거래:
4.40
0.17
+4.02%
Cervomed Inc 주식(CRVO)의 최신 뉴스
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results - TipRanks
[8-K] CervoMed Inc. Reports Material Event | CRVO SEC FilingForm 8-K - Stock Titan
CervoMed (CRVO): Analyst Maintains Buy Rating with $31 Price Tar - GuruFocus
CervoMed (CRVO) Showcases Promising Trial Results for Neflamapim - GuruFocus
CervoMed Inc Announces New Data on Neflamapimod In Dementia With Lewy Bodies - marketscreener.com
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod By Investing.com - Investing.com Canada
CervoMed Inc. unveils new analyses linking better neflamapimod outcomes to reduced Alzheimer co-pathology - Traders Union
A blood test flagged which Lewy body dementia patients benefited more - Stock Titan
CRVO: Roth Capital Lowers Price Target, Maintains Buy Rating | C - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target to $21.00 | - GuruFocus
Market Trends: Is CervoMed Inc currently under institutional pressureDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Reports 2025 Results, Advances Neflamapimod Programs - TipRanks
CRVO: Phase 3 DLB trial planned for H2 2026, with cash runway limited to six months - TradingView
CervoMed (CRVO) widens 2025 loss as cash runway falls to six months - Stock Titan
Aug Macro: Is CervoMed Inc stock overvalued or fairly pricedWeekly Trading Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
H.C. Wainwright reiterates CervoMed stock rating on conference data - Investing.com
CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates - TradingView
H.C. Wainwright reiterates CervoMed stock rating on conference data By Investing.com - Investing.com UK
CervoMed Inc. Reports Positive Phase 2b Clinical Data and Plans for Phase 3 Trial in Dementia with Lewy Bodies - Quiver Quantitative
Dementia drug CervoMed readies 2026 trials on six‑month cash runway - Stock Titan
CervoMed (CRVO) Maintains Current Analyst Ratings and Price Targ - GuruFocus
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs - TipRanks
CervoMed Inc. (CRVO) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
CervoMed Inc. Annual Report 2025: Strategy, Key Terms, and Forward-Looking Statements for Age-Related Brain Disorders - Minichart
CRVO: Neflamapimod achieved robust, durable efficacy in DLB without AD co-pathology, advancing to Phase 3 - TradingView
CervoMed 10-K: $4.01M Grant Revenue; Net Loss $26.97M, $(2.98) EPS - TradingView
CRVO: Net loss widened to $27.0 million in 2025; ongoing operations depend on new capital - TradingView
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CervoMed Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference - Sahm
CervoMed (CRVO) to Showcase Neflamapimod Advancements at AD/PD 2 - GuruFocus
CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference - Bitget
CervoMed Inc neflamapimod selected by UK platform for ALS treatment assessment - Traders Union
Is CervoMed Inc. stock a good choice for value investorsWeekly Gains Report & Short-Term Trading Opportunity Alerts - Naître et grandir
CervoMed to Participate in Upcoming Investor Conferences - Sahm
Analysts Offer Insights on Healthcare Companies: CervoMed (CRVO) and Delcath Systems (DCTH) - The Globe and Mail
D. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - Defense World
Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus
CervoMed sets 50mg dose for phase 3 dementia trial By Investing.com - Investing.com Canada
CervoMed Finalizes Formulation and Dosing Regimen for Phase 3 Trial in Dementia with Lewy Bodies - geneonline.com
CervoMed Advances Neflamapimod With Phase 1 Completion - TipRanks
CervoMed (CRVO) Analyst Rating Update: Buy Rating Maintained by D. Boral Capital | CRVO Stock News - GuruFocus
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com Nigeria
Phase 3 neflamapimod dose set at 50 mg, CervoMed Inc. asserts - Traders Union
CervoMed Inc. Announces Successful Phase 1 Study of Stable Crystal Form of Neflamapimod and Planned Phase 3 Trial Dosing Regimen for Dementia with Lewy Bodies - Quiver Quantitative
CervoMed picks 50mg dose for dementia drug after Phase 1 study - Stock Titan
Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Guidance Update: Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
How do insiders feel about CervoMed Inc2025 Institutional Moves & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Analysts Set CervoMed Inc. Target Price at $22.17 - National Today
Stock Analysis: What is CervoMed Incs revenue forecastJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn
CRVOCervoMed Latest Stock News & Market Updates - Stock Titan
Analysts’ Top Healthcare Picks: CervoMed (CRVO), Insulet (PODD) - The Globe and Mail
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target - TipRanks
CervoMed’s neflamapimod selected for UK ALS trial platform By Investing.com - Investing.com Canada
CervoMed’s Neflamapimod Added to U.K. ALS Platform - TipRanks
CervoMed's neflamapimod selected for UK EXPERTS-ALS; first ALS dosing expected by end of 2026 - TradingView
Neflamapimod joins UK EXPERTS-ALS platform for ALS at CervoMed (NASDAQ: CRVO) - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):